BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
BioCryst Pharma (BCRX) PT Raised to $11 at Jefferies
August 5, 2024 4:01 PM EDTJefferies analyst Maury Raycroft raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $11.00 (from $10.00) while maintaining a Buy rating.
The analyst comments "Focus heading into 2Q was on Orladyo sales, and BCRX delivered another commercial surprise (stock +5.5%) and increased guidance due to... More
